Efficacy and safety of baricitinib in hospitalized adults with severe or critical COVID-19 (Bari-SolidAct): a randomised, double-blind, placebo-controlled phase 3 trial

Press/Media

Period	10 Jan 2023

Media coverage

Title	Efficacy and safety of baricitinib in hospitalized adults with severe or critical COVID-19 (Bari-SolidAct): a randomised, double-blind, placebo-controlled phase 3 trial
Media name/outlet	Critical Care
Country/Territory	United States
Date	10/01/23
URL	https://ccforum.biomedcentral.com/articles/10.1186/s13054-022-04205-8
Persons	Sarah O'Connell, Edmund Manning, Joe Eustace, Robert Sheehan